Randomized placebo controlled trials of n-acetyl cysteine as adjunct therapy for schizophrenia and bipolar disorder
Bush, Ashley, Dean, Olivia, Copolov, D. L. and Berk, M. 2009, Randomized placebo controlled trials of n-acetyl cysteine as adjunct therapy for schizophrenia and bipolar disorder, in WFSBP Congress 2009 : Proceedings of the 9th World Congress of Biological Psychiatry, World Federation of Societies of Biological Psychiatry,.
Attached Files
(Some files may be inaccessible until you login with your Deakin Research Online credentials)
Name
Description
MIMEType
Size
Downloads
Title
Randomized placebo controlled trials of n-acetyl cysteine as adjunct therapy for schizophrenia and bipolar disorder
WFSBP Congress 2009 : Proceedings of the 9th World Congress of Biological Psychiatry
Editor(s)
[Unknown]
Publication date
2009
Publisher
World Federation of Societies of Biological Psychiatry
Summary
Glutathione is the principal antioxidant of the brain. There is evidence of oxidative stress, lowered brain glutathione and genetic linkage involve glutathione metabolic genes in schizophrenia and bipolar disorder. N-acetyl cysteine (NAC) is a safe, orally bioavailable, precursor of glutathione. NAC has been shown to reverse animal models of oxidative stress, and raises brain glutathione levels.
Notes
Presented during a Free Communication session
Language
eng
Field of Research
119999 Medical and Health Sciences not elsewhere classified
Socio Economic Objective
970111 Expanding Knowledge in the Medical and Health Sciences